The Tomosynthesis Mammographic Imaging Screening Trial (TMIST), the first randomized trial to compare two types of digital mammography for breast cancer screening, is now open for enrollment.
Patient safety is of paramount importance in cancer clinical trials. This new video discusses how patient rights and safety are protected in clinical research.
FDA has approved tisagenlecleucel (Kymriah™), a type of immunotherapy called CAR T-cell therapy, for some children and young adults with advanced acute lymphoblastic leukemia (ALL). The approval was based on a multicenter clinical trial involving 63 children and young adults with B-cell ALL that had relapsed or resisted treatment.
FDA has granted full approval to olaparib tablets (Lynparza®) as maintenance treatment for patients with recurrent ovarian cancer who are having partial or complete responses to platinum-based chemotherapy. The approval is based on findings from two randomized clinical trials involving patients with recurrent ovarian cancer.
Taking part in a cancer treatment clinical trial is a big decision. This page presents a list of questions you may want to ask your doctor about before deciding to participate in a clinical trial.
NCI-Supported Clinical Trials that Are Recruiting Patients
This phase 2 trial studies how well lutetium Lu 177-DOTA-TATE works in treating patients with pheochromocytoma or paraganglioma that has spread to other places in the body and cannot be removed by surgery.
This phase 1 trial studies the safety of T-cell immunotherapy and aldesleukin in treating patients with vulvar high-grade intraepithelial lesions (HSIL) that are human papilloma virus-16 (HPV-16) positive and which surgery has failed to control. T cells will be harvested from the patient’s blood and genetically engineered to express a receptor that recognizes the E6 protein on cells infected with HPV-16. The genetically engineered T cells will then be put back into the patient.
This phase 1/2 trial will assess the safety and efficacy of anti-KRAS G12V peripheral blood lymphocytes, chemotherapy, and aldesleukin, and see how well they work in treating patients with KRAS G12V-positive and HLA-A*1101-positive cancer. T cells will be harvested from the patient’s blood and genetically engineered to express a receptor that recognizes G12V-mutated variant of KRAS. The genetically engineered T cells will then be put back into the patient.
